May. 14 at 7:15 AM
$CAI
Caris delivered a blockbuster Q4, with total revenue accelerating 125% YoY to
$292.9M and net income surging to
$82M. The company has decisively crossed into profitable territory, reversing years of heavy cash burn. Gross margins expanded an incredible 2,000 basis points to 75%, reflecting massive operating leverage on their sequencing platform. However, the headline 199% growth in molecular profiling revenue is distorted by
$81M in prior-period true-ups. While the underlying clinical volume growth of 20% is stable, investors must separate the accounting catch-ups from the core operational momentum. Guidance for FY26 promises the
$1B revenue milestone, indicating management believes the structural ASP (Average Selling Price) improvements are durable.
